Social Media Perceptions Among Young Adults With Cancer - Online Experiment 1
NCT07928323, Not applicable, Completed, UNC Lineberger Comprehensive Cancer Center
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Social Media Perceptions Among Young Adults With Cancer - Online Experiment 1 | ClinicalTrials.gov |
| NCT number | NCT07928323 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 505 participants, actual | ClinicalTrials.gov |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center | ClinicalTrials.gov |
| Conditions | Cancer, Cancer Survivors | ClinicalTrials.gov |
| Interventions | Connected advocate advice, Lonely advocate advice, Peer-to-peer sharing, Clinician advice, Control messages | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Perceived Message Effectiveness (Single-Item Self-Report, 5-Point Scale) | Baseline, Up to 1 hour | After viewing each of 5 social media posts, participants answered one item: "How much does this post make you want to connect in person with people you barely know more often?" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater perceived message effectiveness. Ratings were compared across experimental conditions and message types. | ClinicalTrials.gov |
| Secondary | Positive Affect (Single-Item Self-Report, 5-Point Scale) | Baseline, Up to 1 hour | After viewing each of 5 social media posts, participants answered one item: "How good does viewing this post make you feel?" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater positive affect. Ratings were compared across experimental conditions and message types. | ClinicalTrials.gov |
| Secondary | Perceived Social Presence (Single Item Adapted From Lazard et al., 2020; 5-Point Scale) | Baseline, Up to 1 hour | After viewing each of 5 social media posts, participants answered one item: "When viewing this post, how much do you feel as if someone is talking to you?" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater perceived social presence. Ratings were compared across experimental conditions and message types. | ClinicalTrials.gov |
| Secondary | Message Relevance (Single Item Adapted From Jensen et al., 2024; 5-Point Scale) | Baseline, Up to 1 hour | After viewing each of 5 social media posts, participants answered one item: "How relevant is this post to you?" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater perceived relevance. Ratings were compared across experimental conditions and message types. | ClinicalTrials.gov |
| Secondary | Attention (Single Item Adapted From Sutfin et al., 2019; 5-Point Scale) | Baseline, Up to 1 hour | After viewing each of 5 social media posts, participants answered one item: "How much does this post grab your attention?" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater attention. Ratings were compared across experimental conditions and message types. | ClinicalTrials.gov |
| Secondary | Perceived Authenticity (Single-Item Self-Report, 5-Point Scale) | Baseline, Up to 1 hour | After viewing each of 5 social media posts, participants answered one item: "How much do you think this post shares a real perspective?" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater perceived authenticity. Ratings were compared across experimental conditions and message type. | ClinicalTrials.gov |
| Other | Negative Affect, Unintended Reaction (Single-Item Self-Report, 5-Point Scale) | Baseline, Up to 1 hour | After viewing each of 5 social media posts, participants answered one item: "How bad does viewing this post make you feel?" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater negative affect (a less favorable reaction). Ratings were compared across experimental conditions and message types. | ClinicalTrials.gov |
| Other | Reactance, Unintended Reaction (Single Item Adapted From Hall et al., 2017; 5-Point Scale) | Baseline, Up to 1 hour | After viewing each of 5 social media posts, participants answered one item: "How much does this post annoy you?" Response options ranged from 1 (not at all) to 5 (very much); higher scores indicate greater reactance (a less favorable reaction). Ratings were compared across experimental conditions and message types. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)